Robot-assisted surgery has evolved into a crucial treatment for prostate cancer(PCa).However,from its appearance to today,brain-computer interface,virtual reality,and metaverse have revolutionized the field of robot-a...Robot-assisted surgery has evolved into a crucial treatment for prostate cancer(PCa).However,from its appearance to today,brain-computer interface,virtual reality,and metaverse have revolutionized the field of robot-assisted surgery for PCa,presenting both opportunities and challenges.Especially in the context of contemporary big data and precision medicine,facing the heterogeneity of PCa and the complexity of clinical problems,it still needs to be continuously upgraded and improved.Keeping this in mind,this article summarized the 5 stages of the historical development of robot-assisted surgery for PCa,encompassing the stages of emergence,promotion,development,maturity,and intelligence.Initially,safety concerns were paramount,but subsequent research and engineering advancements have focused on enhancing device efficacy,surgical technology,and achieving precise multi modal treatment.The dominance of da Vinci robot-assisted surgical system has seen this evolution intimately tied to its successive versions.In the future,robot-assisted surgery for PCa will move towards intelligence,promising improved patient outcomes and personalized therapy,alongside formidable challenges.To guide future development,we propose 10 significant prospects spanning clinical,research,engineering,materials,social,and economic domains,envisioning a future era of artificial intelligence in the surgical treatment of PCa.展开更多
Tb the Editor:Bladder cancer(BCa)is one of the most common urological malignant tumors.With a worldwide incidence of 573,278 cases in 2020,it ranks eleventh among all tumors.Despite having different approved immune ch...Tb the Editor:Bladder cancer(BCa)is one of the most common urological malignant tumors.With a worldwide incidence of 573,278 cases in 2020,it ranks eleventh among all tumors.Despite having different approved immune checkpoint inhibitors for use among patients with BCa,the response rate to those drugs has remained limited,varying from 20%to 40%.展开更多
基金supported by the Fundamental Research Funds for the Central Universities(2023SCU12057)the National Natural Science Foundation of China(82373106,82372831,and 32270690).
文摘Robot-assisted surgery has evolved into a crucial treatment for prostate cancer(PCa).However,from its appearance to today,brain-computer interface,virtual reality,and metaverse have revolutionized the field of robot-assisted surgery for PCa,presenting both opportunities and challenges.Especially in the context of contemporary big data and precision medicine,facing the heterogeneity of PCa and the complexity of clinical problems,it still needs to be continuously upgraded and improved.Keeping this in mind,this article summarized the 5 stages of the historical development of robot-assisted surgery for PCa,encompassing the stages of emergence,promotion,development,maturity,and intelligence.Initially,safety concerns were paramount,but subsequent research and engineering advancements have focused on enhancing device efficacy,surgical technology,and achieving precise multi modal treatment.The dominance of da Vinci robot-assisted surgical system has seen this evolution intimately tied to its successive versions.In the future,robot-assisted surgery for PCa will move towards intelligence,promising improved patient outcomes and personalized therapy,alongside formidable challenges.To guide future development,we propose 10 significant prospects spanning clinical,research,engineering,materials,social,and economic domains,envisioning a future era of artificial intelligence in the surgical treatment of PCa.
基金the National Key Research and Development Program of China(No.SQ2017YFSF090096)the National Natural Science Foundation of China(Nos.81702536,81974099,82070784).
文摘Tb the Editor:Bladder cancer(BCa)is one of the most common urological malignant tumors.With a worldwide incidence of 573,278 cases in 2020,it ranks eleventh among all tumors.Despite having different approved immune checkpoint inhibitors for use among patients with BCa,the response rate to those drugs has remained limited,varying from 20%to 40%.
